References
Gurrera RJ, Caroff SN, Cohen A, Carroll BT, DeRoos F, Francis A, Frucht S, Gupta S, Levenson JL, Mahmood A, Mann SC, Policastro MA, Rosebush PI, Rosenberg H, Sachdev PS, Trollor JN, Velamoor VR, Watson CB, Wilkinson JR (2011) An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. J Clin Psychiatry 72:1222–1228
Hall RCW, Hall RCW, Chapman M (2006) Neuroleptic malignant syndrome in the elderly: diagnostic criteria, incidence, risk factors, pathophysiology, and treatment. Clin Geriatrics 14:39–46
Strawn JR, Keck PE Jr, Caroff SN (2007) Neuroleptic malignant syndrome. Am J Psychiatry 164:870–876
Wait SD, Ponce FA, Killory BD, Wallace D, Rekate HL (2009) Neuroleptic malignant syndrome from central nervous system insult: 4 cases and a novel treatment strategy. J Neurosurg Pediatr 4:217–221
Krauss JK, Regel JP, Droste DW, Orszagh M, Borremans JJ, Vach W (1997) Movement disorders in adult hydrocephalus. Mov Disord 12:53–60
Mandir AS, Hilfiker J, Thomas G, Minahan RE, Crawford TO, Williams MA, Rigamonti D (2007) Extrapyramidal signs in normal pressure hydrocephalus: an objective assessment. Cerebrospinal Fluid Res 4:7
Thomas A, Onofrj M (2005) Akinetic crisis, acute akinesia, neuroleptic malignant-like syndrome, Parkinsonism-hyperpyrexia syndrome, and malignant syndrome are the same entity and are often independent of treatment withdrawal. Mov Disord 20:1671–1672
Onofrj M, Thomas A (2005) Acute akinesia in Parkinson disease. Neurology 64:1162–1169
Abi-Dargham A, Gandelman MS, DeErausquin GA, Zea-Ponce Y, Zoghbi SS, Baldwin RM, Laruelle M, Charney DS, Hoffer PB, Neumeyer JL, Innis RB (1996) SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of beta-CIT. J Nucl Med 37:1129–1133
Buchert R, Berding G, Wilke F, Martin B, von Borczyskowski D, Mester J, Brenner W, Clausen M (2006) IBZM tool: a fully automated expert system for the evaluation of IBZM SPECT studies. Eur J Nucl Mod Mol Imaging 33:1073–1083
Darcourt J, Booij J, Tatsch K, Varrone A, Vander Borght T, Kapucu OL, Någren K, Nobili F, Walker Z, Van Laere K (2010) EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging 37:443–450
Lu CS, Ryu SJ (1991) Neuroleptic malignant-like syndrome associated with acute hydrocephalus. Mov Disord 6:381–383
Conflicts of interest
The authors declare that there is no conflict of interest.
Ethical standard
All human studies must state that they have been approved by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jussen, D., Sprung, C., Buchert, R. et al. Hydrocephalus-induced neuroleptic malignant-like syndrome with reduced dopamine transporters. J Neurol 260, 2182–2184 (2013). https://doi.org/10.1007/s00415-013-7026-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-013-7026-8